Drug intelligence / Profile preview

TMX-101

Development stage: Phase 2
Lead developer: Telormedix
Modality: Small Molecules
Administration: Intravesical

Overview

TMX-101 (Vesimune) is a novel liquid formulation of imiquimod specifically optimized for intravesical delivery in the treatment of non-muscle-invasive bladder cancer (NMIBC). It functions as a toll-like receptor 7 (TLR-7) agonist, stimulating the immune system to attack cancer cells present on the bladder surface. The drug works by triggering immune responses, including the production of proinflammatory cytokines and increasing urinary cytokine levels such as IL-6 and IL-18.

Brand names: Vesimune
Other names: UGN 201UGN201UGN-201imiquimod intravesicular

Targets

TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on TMX-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TMX-101.

Explore the full profile